Read this month’s issue of New at CADTH. Here, you’ll find the latest information on our products and services, corporate news, and news flashes of upcoming events across Canada.
Today CADTH is pleased to announce operational changes that will enhance our Common Drug Review and pan-Canadian Oncology Drug Review programs. These changes reflect our careful consideration of stakeholder feedback and input from the participating jurisdictions.
For complete details regarding the revised biosimilar review process and applicati...
CADTH has implemented a new fee structure that applies to both the Common Drug Review and pan-Canadian Oncology Drug Review programs. The new Guidelines on Application Fees for CADTH Pharmaceutical Reviews replace the separate application fee guidelines which previously existed for each program.
Other important highlights include:
a reduced fee...
Matthew Seftel, MD, MPH, FRCP, FRCPC
Head, Department of Medical Oncology and Hematology, CancerCare Manitoba
Associate Professor, Section of Hematology/Oncology, Department of Internal Medicine, University of Manitoba
For diseases caused by inherited or acquired genetic mutations, the ideal remedy is to correct the relevant mutations. Recently,...
A draft report on Community Water Fluoridation Programs is now available for feedback from all interested stakeholders.
Call for Feedback
Feedback Due By
Community Water Fluoridation Programs
Submit Stakeholder Feedback
List of Included Studies
Health Technology Assessment